企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
GI Innovation Inc. is a biotechnology company that researches and develops next-generation immunotherapies based on fusion proteins, holding a variety of new immunotherapy drug pipelines, including its core pipeline assets GI-101/GI-102, immuno-oncology drugs, and GI-301, an allergy treatment. The company is composed of experts in biopharmaceutical R&D and technology commercialization, including basic scientists in the pharmaceutical/bio field, process development specialists, and clinical development and technology transfer specialists, and on this basis it has secured platform technology for discovering new fusion protein drugs, its own process development technology, and clinical development capabilities based on unmet medical needs in target markets.
代表理事
장명호, 홍준호(각자대표이사)
成立日期
2017年7月19日
法人类型
韩国创业板
行业分类
Research and experimental development on medical sciences and pharmacy
法人注册号
14521-0021112
营业执照号
682-86-00771
电话号码
02-404-2003
传真号码
02-2054-8609
公司地址
167 Songpa-daero, Songpa-gu, Seoul
产品与服务
评论